Could antidepressant combat lethal lung cancer? - KTVN Channel 2 - Reno Tahoe News Weather, Video -

Could antidepressant combat lethal lung cancer?

Updated: Sep 27, 2013 09:22 AM
© CDC / Dr. Thomas Hooten © CDC / Dr. Thomas Hooten
  • Wendy Damonte's Health Watch ReportsMore>>

  • Request Remind Me 2 Kit

    Request a Remind Me 2 Kit

         More >>
  • KTVN's 7th Annual 'Give 2 Live' Blood Drive a Success

    KTVN's 7th Annual 'Give 2 Live' Blood Drive a Success

    Our area blood bank is replenishing its stock of life-saving blood -- thanks to you, our viewers. We held our 7th Annual 'Give 2 Live' Blood Drive inside the Atlantis Casino Resort Spa on Monday. We collected more than 200 units of blood.More >>
    Our area blood bank is replenishing its stock of life-saving blood -- thanks to you, our viewers. We held our 7th Annual 'Give 2 Live' Blood Drive inside the Atlantis Casino Resort Spa on Monday. We collected more than 200 units of blood.
    More >>
  • Ask the Doctor: Pediatric Dentistry

    Monday, July 21 2014 6:28 PM EDT2014-07-21 22:28:59 GMT
    When should your child's first visit to the dentist be? Find out in tonight's Ask the Doctor segment.More >>
    When should your child's first visit to the dentist be? Find out in tonight's Ask the Doctor segment.More >>

FRIDAY, Sept. 27 (HealthDay News) -- An older and little-used class of antidepressants may help combat a particularly deadly form of lung cancer, according to a new study.

Using a unique computer program, researchers from the Stanford University School of Medicine identified tricyclic antidepressants as a potential treatment for small cell lung cancer. This class of drugs was introduced decades ago and is still approved for use in the United States, but has been supplanted by newer antidepressants with fewer side effects.

Follow-up experiments showed that the tricyclic antidepressant called imipramine (Tofranil), was effective against human small cell lung cancer cells grown in the laboratory and growing as tumors in mice. The drug activated a self-destruction pathway in the cancer cells and slowed or blocked the spread of cancer in mice.

Imipramine maintained its effectiveness regardless of whether the cancer cells had previously been exposed, and become resistant, to traditional chemotherapy treatments, according to the study, which was published online Sept. 27 in the journal Cancer Discovery.

Because tricyclic antidepressants already have U.S. Food and Drug Administration approval for use in people, the Stanford team was quickly able to launch a clinical trial to test imipramine in patients with small cell lung cancer and certain other types of cancer. They are currently recruiting patients for the phase-2 trial.

"We are cutting down the decade or more and the $1 billion it can typically take to translate a laboratory finding into a successful drug treatment to about one to two years and spending about $100,000," study co-senior author Dr. Atul Butte, director of the Center for Pediatric Bioinformatics at Lucile Packard Children's Hospital at Stanford, said in a university news release.

"The five-year survival for small cell lung cancer is only 5 percent," study co-senior author Julien Sage, an associate professor of pediatrics, said in the news release. "There has not been a single efficient therapy developed in the last 30 years. But when we began to test these drugs in human cancer cells grown in a dish and in a mouse model, they worked, and they worked, and they worked."

Another drug, an antihistamine called promethazine (Phenergan), also exhibited the ability to kill cancer cells, according to the researchers.

More information

The U.S. National Cancer Institute has more about small cell lung cancer.

Copyright © 2013 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Sarkes Tarzian, Inc. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.